TrialSpark
16 East 34th Street floor 10
New York
NY
10016
United States
Tel: +1 510-545-3803
Website: http://www.trialspark.com/
About TrialSpark
TrialSpark is a technology-driven drug development company that runs end-to-end clinical trials, focused on bringing new treatments to patients faster and more efficiently.
TrialSpark recently raised their Series C, and is putting the capital to work by in-licensing and co-developing drug programs through in-house development, joint ventures, and NewCos. Together with doctors, patients, and communities, TrialSpark is working to develop the treatments of tomorrow.
7 articles with TrialSpark
-
TrialSpark and Sanofi announced a new partnership to expedite drug development for areas with high unmet needs by licensing or acquiring six mid-to-late-stage drug candidates.
-
TrialSpark announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies
10/4/2022
TrialSpark announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently.
-
TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio
1/10/2022
TrialSpark announced today the formation of High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany.
-
These life sciences companies scored enough capital this week for pumpkin spice and everything nice, and to propel their candidates in the clinic. Here's a look.
-
This week, three global biopharmaceutical companies received over half a billion dollars to support research and development initiatives in the treatment of rare and deadly diseases.
-
TrialSpark and Sanofi announce collaboration to accelerate COPD clinical development
5/26/2021
TrialSpark's technology-enabled clinical trial platform is uniquely equipped to run challenging trials faster and more efficiently by increasing patient access to investigational medicines and dramatically expediting patient recruitment timelines
-
TrialSpark announces addition of key strategic advisor Steve Holtzman
4/20/2021
TrialSpark Inc., a tech-enabled drug development company dedicated to improving the speed, quality, and innovation of clinical trials, announces the addition of life sciences veteran Steve Holtzman as a key strategic advisor